Małgorzata Łukawska, Irena Oszczapowicz
Tygecyklina - nowy antybiotyk glicylocyklinowy
2009-03-25
Tigecycline, the first in a new class antimicrobial the glycylcycline, is recommended for therapy of the patients with difficult to treat bacterial infections. This antibiotic exhibits in vitro strong activity against Gram-positive and Gram-negative aerobic, anaerobic and atypical bacterial species, including many patogens i.e. methicillin-resistant Staphyloccocus aureus, vancomycin-resistant Enterococcus faecalis, Enterococcus faecium and extended spectrum -laktamase-producing Enterobacteriacea. Clinical trials involving patients with complicated skin or abdominal infections demonstrated that tigecycline is effected with only mild to moderate gastrointestinal events such as nausea, vomiting or diarrhea. Tigecycline appears to be a novel expanded spectrum antibiotic.Keywords: minocycline, bacterial infection, atypical organism.